VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Down 55.4% in January

VYNE Therapeutics Inc. (NASDAQ:VYNE) was the recipient of a large decrease in short interest during the month of January. As of January 15th, there was short interest totaling 752,574 shares, a decrease of 55.4% from the December 31st total of 1,689,232 shares. Approximately 2.3% of the shares of the company are sold short. Based on an average trading volume of 461,342 shares, the short-interest ratio is presently 1.6 days. Based on an average trading volume of 461,342 shares, the short-interest ratio is presently 1.6 days. Approximately 2.3% of the shares of the company are sold short.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of VYNE Therapeutics in a report on Wednesday, January 21st. Wall Street Zen cut shares of VYNE Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday. Three investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Reduce” and an average target price of $4.50.

VYNE Therapeutics Stock Performance

Shares of NASDAQ VYNE opened at $0.56 on Thursday. VYNE Therapeutics has a one year low of $0.28 and a one year high of $2.94. The firm has a market capitalization of $18.80 million, a P/E ratio of -0.72 and a beta of 1.95. The company’s fifty day moving average is $0.50 and its two-hundred day moving average is $0.48.

VYNE Therapeutics (NASDAQ:VYNE) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.02. The firm had revenue of $0.17 million during the quarter, compared to analysts’ expectations of $0.13 million. VYNE Therapeutics had a negative net margin of 6,425.19% and a negative return on equity of 80.84%. On average, sell-side analysts forecast that VYNE Therapeutics will post -0.97 earnings per share for the current fiscal year.

Institutional Investors Weigh In On VYNE Therapeutics

Several institutional investors have recently modified their holdings of VYNE. Adage Capital Partners GP L.L.C. increased its stake in VYNE Therapeutics by 87.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 644,134 shares of the company’s stock valued at $1,063,000 after purchasing an additional 300,000 shares in the last quarter. Baker BROS. Advisors LP acquired a new stake in VYNE Therapeutics in the third quarter valued at $285,000. Shay Capital LLC purchased a new position in shares of VYNE Therapeutics in the third quarter valued at $165,000. Two Sigma Investments LP purchased a new position in shares of VYNE Therapeutics in the third quarter valued at $74,000. Finally, Boothbay Fund Management LLC acquired a new position in shares of VYNE Therapeutics during the 2nd quarter worth $176,000. Hedge funds and other institutional investors own 83.78% of the company’s stock.

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.